# Appendix 3Y

Rule 3.19A.2

# **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| Name of entity     | Australian Pharmaceutical Industries Limited |  |
|--------------------|--|--|
| ABN 57 000 004 320 |  |  |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| Name of Director    | Mark Smith       |
|---------------------|------------------|
| Date of last notice | 16 November 2017 |

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Direct or indirect interest   | Indirect  |  |
|---|---|--|
| Nature of indirect interest<br>(including registered holder)<br>Note: Provide details of the circumstances giving rise to the relevant<br>interest.<br>Date of change | The registered holder is Mark and Anne<br>Smith Super Fund Pty Ltd as trustee for<br>Mark and Anne Smith SF A/C, of which the<br>Director is a director and beneficial owner.<br>23 November 2017 |  |
| No. of securities held prior to change  | 90,000 ordinary shares  |  |
| Class   | Fully paid ordinary shares  |  |
| Number acquired   | 10,000  |  |
| Number disposed   | Nil   |  |
| Value/Consideration<br>Note: If consideration is non-cash, provide details and estimated valuation  | \$14,650.00   |  |
| No. of securities held after change   | 100,000 ordinary shares   |  |

<sup>+</sup> See chapter 19 for defined terms.

| Nature of change   | On-market trade |  |
|--|-----------------|--|
| Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back |                 |  |
|  |                 |  |
|  |                 |  |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Detail of contract   | n/a |
|--|-----|
| Nature of interest   |     |
| Name of registered holder<br>(if issued securities)  |     |
| Date of change   |     |
| No. and class of securities to<br>which interest related prior to<br>change<br>Note: Details are only required for a contract in relation<br>to which the interest has changed |     |
| Interest acquired  |     |
| Interest disposed  |     |
| Value/Consideration<br>Note: If consideration is non-cash, provide details and an<br>estimated valuation   |     |
| Interest after change  |     |

## Part 3 – +Closed period

| Were the interests in the securities or contracts detailed<br>above traded during a <sup>+</sup> closed period where prior | n/a |
|--|-----|
| written clearance was required?  |     |
| If so, was prior written clearance provided to allow the trade to proceed during this period?                              |     |
| If prior written clearance was provided, on what date was this provided?   |     |

<sup>+</sup> See chapter 19 for defined terms.